Centocor Looks Ahead
Anticipating Food and Drug Administration approval of Centoxin, potentially the first therapeutic drug based on mononoclonal antibody technology, Centocor Inc., has announced plans to triple the size of its workforce in Malvern, Pa., the 11-year-old firm's headquarters. The four-year expansion, financed in part by $10.5 million in low-interest state loans, would add 1,000 new jobs. Most of the increase will be devoted to Centoxin production, but Charles Cabot, vice-president of corporate communications at Centocor, says he expects a "substantial" expansion of the company's research division once the Gram-negative sepsis drug is in production.
Sweeping The Stars One of the unfortunate byproducts of man in space is man's debris in space, the assorted bits and pieces of spent rocket boosters and wrecked satellites that have collected in orbit during the last three decades. Now two inventors working for General Research Corp. in Vienna, Va., have received a patent ...
